Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of lenalidomide + rituximab + IMED in relapsed/refractory non-GCB DLBCL
ChiCTR2000029385Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, rituximab, ifosfamide, methotrexate, etoposide and 1 more in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective response rate. Started Jan 2013; status: recruiting.
02
Drugs
lenalidomiderituximabifosfamidemethotrexateetoposide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2000029385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029385.